Taiwan Bio Therapeutics Co., Ltd. engages in the research and development, manufacture, and sale of cell therapy. It also provides contract development and manufacturing organization (CDMO) services. Its products include allogeneic hypoxia-induced bone marrow mesenchymal stem cells produced through hypoxia induction platform; allogeneic precision cell bank mesenchymal stem cells produced through cell titer analysis and screening, and precision cell bank mass production and process scale-up platform; and allogeneic genetically modified bone marrow mesenchymal stem cells produced through cell gene modification technology, and integrated gene-modified cell mas production platform. The company was founded on July 25, 2014 and is headquartered in Hsinchu, Taiwan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company